Effect of a non antihypertensive dose of ramipril on the plasma and tissu renin-angiotensin system in TGR (mRen2) 27 rat

被引:0
|
作者
Grima, M [1 ]
Anjuère, J
Ingert, C
Coquard, C
Steger, J
Barthelmebs, M
Imbs, JL
机构
[1] Univ Strasbourg 1, Inst Pharmacol, Fac Med, Strasbourg, France
[2] Hop Univ, Serv Hypertens, Malad Vasc & Pharmacol Clin, Strasbourg, France
来源
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is admitted that low dose of angiotensin converting enzyme (ACE) inhibitors allows the regression of left ventricular hypertrophy (HVG) in experimental models where plasma renin activity (PRA) is high. The use of low dose of ramipril, an ACE inhibitor, make it possible to explore the place of cardiac renin-angiotensin system (RAS) in the regression of HVG independently of blood pressure (BP). Twenty rats TGR (mRen2) 27, heterozygous male, 10 weeks old were treated by daily oral gavage during 6 weeks by 10 mug/kg/jour ramipril or distilled water and compared to 10 normotensive Sprague Dawley (SD) rats. BID was measured. After the period of treatment, plasma, left kidney and the ventricles were removed. On each tissue samples and plasma, angiotensinogen (Aogen), the renin activity, angiotensins I (Ang II) and II (Ang II) were determined by radioimmuno assay and the activity of ACE was measured by fluorimetry. BP does not differ between treated and untreated groups during 6 weeks of treatment but is significantly higher compared to SID rats. PRA of untreated rats is high (36 +/-5 ng Ang I/mL/h). However, treatment did not make it possible to decrease HVG. In plasma and kidney treatment's effect on SRA is confirmed by the increase in renin activity (plasma: 63 +/-9 vs 36 +/-5 ng Ang I/mL/h; kidney: 127.1 +/- 11 vs 92 +/-7 pg Ang I/g/h) which is accompanied by an increase of Ang I rates (plasma: 297 +/- 31 vs 15 +/- 10 fmol/mL; kidney: 241 +/- 37 vs 160 +/- 12 fmol/g) and of the reduction in Aogen. An inhibition of ACE is perceptible with low dose of ramipril in heart (left ventricle: 1.7 +/-0.1 vs 2.5 +/-0.3 nmol HisLeu/min/mg protein), but it does not appear significant modifications of the other elements of the RAS in this tissue. The Ang OO cardiac rates are probably not solely defined by cardiac ACE activity, other ways of synthesis being described. The absence of regression of the HVG in TGR (mRen2) 27 rat with low dose of ramipril could be related to the absence of effect on cardiac Ang II rates. In addition, the relation between high PRA rates and the effectiveness of low dose of ACE inhibitor in the HVG are not confirmed.
引用
收藏
页码:805 / 812
页数:8
相关论文
共 50 条
  • [21] Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade
    Bohm, M
    Lippoldt, A
    Wienen, W
    Ganten, D
    Bader, M
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 1996, 164 : 217 - 221
  • [22] ESTROGEN PROTECTS TRANSGENIC (MREN2)27 HYPERTENSIVE RATS BY SHIFTING THE VASODILATOR-VASOCONSTRICTOR BALANCE OF THE RENIN-ANGIOTENSIN SYSTEM
    LI, P
    FERRARIO, CM
    GANTEN, D
    BROSNIHAN, K
    CIRCULATION, 1995, 92 (08) : 2006 - 2006
  • [23] ENHANCED ADRENAL RENIN AND ALDOSTERONE BIOSYNTHESIS DURING SODIUM RESTRICTION IN TGR (MREN2)27
    RUBATTU, S
    ENEA, I
    GANTEN, D
    SALVATORE, D
    CONDORELLI, G
    CONDORELLI, G
    RUSSO, R
    ROMANO, M
    GIGANTE, B
    TRIMARCO, B
    VOLPE, M
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1994, 267 (04): : E515 - E520
  • [24] Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats
    Bohlender, J
    Ménard, J
    Edling, O
    Ganten, D
    Luft, FC
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1998, 274 (05): : H1450 - H1456
  • [25] ANGIOTENSIN AND BRADYKININ PEPTIDES IN THE TGR(MREN-2)27 RAT
    CAMPBELL, DJ
    RONG, P
    KLADIS, A
    REES, B
    GANTEN, D
    SKINNER, SL
    HYPERTENSION, 1995, 25 (05) : 1014 - 1020
  • [26] (Pro)renin Receptor Inhibition in Diabetic Transgenic mREN2 Rats (TGR(mREN2)27) Upregulates Endothelium-Derived Contractile Factors
    Batenburg, Wendy W.
    van den Heuvel, Mieke
    van Esch, Joep H.
    van Veghel, Richard
    Danser, A. H.
    HYPERTENSION, 2011, 58 (05) : E71 - E72
  • [27] THE ROLE OF THE ADRENAL-GLAND IN HYPERTENSIVE TRANSGENIC RAT TGR(MREN2)27
    SANDER, M
    BADER, M
    DJAVIDANI, B
    MASERGLUTH, C
    VECSEL, P
    MULLINS, J
    GANTEN, D
    PETERS, J
    ENDOCRINOLOGY, 1992, 131 (02) : 807 - 814
  • [28] Functional evidence of cardiovascular pathophysiology in the TGR(mRen2)27 transgenic rat.
    Gelband, CH
    Pachori, A
    Kochera, R
    Numan, MT
    Byrne, BJ
    Katovich, MJ
    Ganten, D
    Ferrario, CM
    Raizada, MK
    FASEB JOURNAL, 1999, 13 (04): : A342 - A342
  • [29] From genotype to phenotype - Behavior of the transgenic rat TGR(mRen2)27 as an example
    Voigt, JP
    Rex, A
    Bader, M
    Fink, H
    REVIEWS IN THE NEUROSCIENCES, 2000, 11 (01) : 37 - 45
  • [30] Spironolactone prevents activation of the intrarenal renin-angiotensin system and increases survival in (mRen2) 27 transgenic rats with malignant hypertension.
    Wong, DL
    Chappell, MC
    Ferrario, CM
    Ganten, D
    Diz, DI
    HYPERTENSION, 2000, 36 (04) : 724 - 724